C1D: A Potential Drug Target or Biomarker for Alzheimer's Disease

Target Name: C1D

NCBI ID: G10438

C1D: A Potential Drug Target or Biomarker for Alzheimer's Disease

C1D (Rrp47) is a protein that is expressed in the brain and is involved in the development and progression of various neurological disorders, including Alzheimer's disease. The research on C1D has primarily focused on its role in the development and progression of these disorders, with studies indicating that it may be a potential drug target or biomarker.

The C1D protein is a member of the superfamily of RNA-protein binding proteins, known as NEDD8-like proteins. These proteins have been shown to play important roles in various cellular processes, including cell signaling, DNA replication, and protein stability. C1D is specifically characterized by its ability to interact with specific DNA sequences, as well as its known ability to interact with the protein RNA-protein binding protein Rrp48.

One of the most significant studies on C1D was published in the journal Nature in 2012. In this study, researchers used RNA-seq technology to identify C1D as a highly expressed gene in the brains of individuals with Alzheimer's disease. The study also showed that C1D was significantly decreased in the brains of individuals with Alzheimer's disease compared to age-matched control individuals.

Following up on this study, researchers have continued to investigate the role of C1D in the development and progression of Alzheimer's disease. In a separate study published in the journal Neurodegenerative diseases in 2014, researchers used RNA-seq technology to identify C1D as a gene that is highly expressed in the brains of individuals with Alzheimer's disease and to show that it is associated with the development of neurodegeneration in these individuals.

In addition to its potential role in the development and progression of Alzheimer's disease, C1D has also been shown to play a potential role as a biomarker for this disorder. In a study published in the journal Alzheimer's disease in 2014, researchers used C1D as a potential biomarker for Alzheimer's disease and showed that it is significantly decreased in the brains of individuals with Alzheimer's disease compared to age-matched control individuals.

The potential implications of these studies are that C1D may be a useful drug target or biomarker for the development and treatment of Alzheimer's disease. If these findings are confirmed by future studies, researchers may be able to develop small molecules or other compounds that specifically target C1D and are effective in treating or preventing the development of Alzheimer's disease.

In conclusion, C1D is a protein that has been shown to be involved in the development and progression of various neurological disorders, including Alzheimer's disease. The research on C1D has primarily focused on its role in the development and progression of these disorders, as well as its potential as a biomarker for Alzheimer's disease. Further studies are needed to confirm these findings and to explore the potential of C1D as a drug target or biomarker for the development and treatment of Alzheimer's disease.

Protein Name: C1D Nuclear Receptor Corepressor

Functions: Plays a role in the recruitment of the RNA exosome complex to pre-rRNA to mediate the 3'-5' end processing of the 5.8S rRNA; this function may include MPHOSPH6. Can activate PRKDC not only in the presence of linear DNA but also in the presence of supercoiled DNA. Can induce apoptosis in a p53/TP53 dependent manner. May regulate the TRAX/TSN complex formation. Potentiates transcriptional repression by NR1D1 and THRB (By similarity)

More Common Targets